Seres Therapeutics (MCRB) Operating Leases (2019 - 2026)
Seres Therapeutics (MCRB) posted Operating Leases of $69.6 million for Q1 2026, down 4.05% sequentially from $72.6 million in Q4 2025, and down 13.5% YoY from $80.5 million in Q1 2025.
Seres Therapeutics (MCRB) Operating Leases (2019 - 2026) Analysis & Trends
Seres Therapeutics has reported Operating Leases for 8 years, with the latest figure at $69.6 million in Q1 2026.
- Quarterly Operating Leases fell 13.5% year-over-year to $69.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.6 million (down 13.5% YoY) and the FY2025 annual result came in at $72.6 million, down 12.52% from the prior year.
- Operating Leases declined to $69.6 million in Q1 2026 per MCRB's latest filing, from $72.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $107.9 million in Q4 2022 and troughed at $17.8 million in Q3 2022.
- A 5-year average of $77.9 million and a median of $83.0 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2025: Operating Leases surged 501.08% in 2022, then fell 22.77% in 2025.
- Over 5 years, Operating Leases stood at $107.9 million in 2022, then slipped by 15.09% to $91.7 million in 2023, then fell by 9.48% to $83.0 million in 2024, then decreased by 12.52% to $72.6 million in 2025, then fell by 4.05% to $69.6 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $69.6 million, $72.6 million, and $75.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.82 Mn |
| Mar 31, 2026 | 69.63 Mn |
| Dec 31, 2025 | 72.58 Mn |
| Sep 30, 2025 | 75.33 Mn |
| Jun 30, 2025 | 77.96 Mn |
| Mar 31, 2025 | 80.50 Mn |
| Dec 31, 2024 | 82.97 Mn |
| Sep 30, 2024 | 85.27 Mn |
| Jun 30, 2024 | 100.94 Mn |
| Mar 31, 2024 | 103.34 Mn |
| Dec 31, 2023 | 91.65 Mn |
| Sep 30, 2023 | 104.86 Mn |
| Jun 30, 2023 | 106.71 Mn |
| Mar 31, 2023 | 106.69 Mn |
| Dec 31, 2022 | 107.94 Mn |
| Sep 30, 2022 | 17.85 Mn |
| Jun 30, 2022 | 19.52 Mn |
| Mar 31, 2022 | 20.35 Mn |
| Dec 31, 2021 | 17.96 Mn |
| Sep 30, 2021 | 12.23 Mn |